The Pebble Labs family of companies all share a common technology platform that we have named Transbiotics™. Transbiotics is the production of double stranded RNA inside naturally occurring bacterium that live within the target host organism. The dsRNA is designed to target and inactivate genes that are essential for the target pathogen to thrive in the host. These genes may be involved in protein synthesis, DNA replication of viruses, RNA synthesis in the virus or other key functions of the pathogen.
Transbiotics Mechanism of Action
The elegance and efficacy of the Transbiotic platform is that both the production and delivery mechanisms utilize the naturally occurring bacteria that already live in the host organism. In animals, these are typically enteric bacteria that live in the gut of the organism. In plants, these are typically endophytic bacteria that live within or on the margins of the cells throughout the plant.
The transformational Transbiotics Technology Platform provides compelling cost, scaling advantages to current or proposed methodologies.
Pebble Labs is developing the transformational science of Transbiotics to sustainably eliminate pathogens in agriculture, aquaculture and vector-borne disease without the use of toxic herbicides, pesticides and antibiotics.
Apart from the inherent high target specificity of Transbiotics, a key advantage is its adaptability to respond in real time to emerging pathogen threats or to the onset of resistance in an evolving targeted pathogen or pest. This capability and high specificity is made possible by genome information resources and technological advances in Next Generation Sequencing. We now not only have access to DNA and RNA sequence information, from an ever-expanding number of organisms across all kingdoms, but we can also return a query result across all genome sequence databases in seconds.
Transbiotics has the potential to reduce years of development into months, from design to market.
The simple use of the BLAST algorithm supports Pebble Labs scientist’s ability to rapidly design new dsRNA molecules – to be manufactured and delivered through the Transbiotics platform – to quickly meet the challenge of emerging pathogen threats, without negative effects to the host organism or ecosystem. With this data, we can engineer new products safely, quickly and inexpensively, without the need for the costly and lengthy development of new chemical compounds or GMO organisms.